Mode
Text Size
Log in / Sign up
Phase 4 N=600 Randomized Treatment

Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali

Diarrhea Rotavirus

Enrolled (actual)
600
Serious AEs
2.5%
Results posted
Dec 2018
Primary outcome: Primary: Number/Percentage of Subjects With Seroconversion for Anti-measles Immunoglobulin G (IgG) Antibody — 246; 255; 2; 3 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
pentavalent rotavirus vaccine (PRV) (Biological); measles vaccine (MV) (Biological); yellow fever vaccine (YFV) (Biological); meningitis conjugate vaccine (PsA-TT-5μg) (Biological)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
PATH
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Number/Percentage of Subjects With Seroconversion for Anti-measles Immunoglobulin G (IgG) Antibody
206; 210; 4; 5; 8; 13
PRIMARY
Number/Percentage of Subjects With Seroresponses for Yellow Fever Neutralizing Antibody
153; 141; 137; 146
SECONDARY
Number/Percentage of Subjects With Seroconversion for Anti-measles Immunoglobulin G (IgG) Antibody
206; 210; 4; 5; 8; 13
SECONDARY
Serum Neutralization Geometric Mean Titers for Yellow Fever Vaccine
2.4; 2.5; 16.8; 15
SECONDARY
Number/Percentage of Subjects With Seroresponses for Meningitis Conjugate Serum Bactericidal Antibody (SBA)
276; 273; 17; 19
SECONDARY
Geometric Mean of Meningitis Serum Bactericidal Antibody Titer
2.8; 3.2
SECONDARY
Number/Percentage of Subjects With Anti-rotavirus Immunoglobulin A (IgA) Titer at Least 3 Times Baseline Value
80; 131; 212; 161
SECONDARY
Number/Percentage of Subjects With Anti-rotavirus IgA Titer of ≥20 Units/mL
172; 218; 120; 74
SECONDARY
Number/Percentage of Subjects With Anti-rotavirus IgA <20 Units/mL at Baseline Visit That Had >=20 Units/mL at Day 28
52; 91; 113; 69
SECONDARY
Number/Percentage of Subjects With Anti-rotavirus IgG Titer at Least 3 Times Baseline Value
77; 168; 216; 125
SECONDARY
Number/Percentage of Subjects With Anti-rotavirus IgG Titer of ≥20 Units/mL
223; 275; 70; 18
SECONDARY
Number/Percentage of Subjects With Anti-rotavirus IgG <20 Units/mL at Baseline Visit That Had >=20 Units/mL at Day 28
29; 76; 63; 15
SECONDARY
Geometric Mean of Anti-rotavirus IgA Concentration
23.7; 25.3; 67.9; 118.4
SECONDARY
Geometric Mean of Anti-rotavirus IgG Concentration
58.9; 62.5; 153.3; 363.6
SECONDARY
Geometric Mean of Anti-rotavirus IgA Among Subjects With <20 Units/mL Concentration at Baseline
5.1; 4.8; 22.2; 41.5
SECONDARY
Geometric Mean of Anti-rotavirus IgG Among Subjects With <20 Units/mL Concentration at Baseline
7.8; 7.4; 28.3; 123.7
SECONDARY
Number/Percentage of Participants Experiencing Immediate Reactions Post-vaccination
0; 0; 300; 300
SECONDARY
Number of Solicited Adverse Reactions (AR) Experienced by Participants
24; 21; 8; 7; 5; 8
SECONDARY
Number/Percentage of Participants Experiencing Serious Adverse Events (SAE)
1; 0; 6; 7; 292; 293

Summary

This study is an evaluation of the immune response to pentavalent rotavirus vaccine (PRV) after an additional fourth dose is given at 9 months of age with local World Health Organization (WHO) Expanded Programme on Immunization (EPI) vaccines in Mali.

Eligibility Criteria

Inclusion Criteria

  • At least 9 months of age through 11 months of age (has not yet reached 1st birthday) at the time of administration of study vaccines.
  • Residence in the study area.
  • At least one parent or guardian who is at least 18 years of age and is willing to provide written informed consent.
  • Generally healthy and free of obvious health problems as established by medical history including physical examination and clinical judgment of the investigator.
  • A child who is fully vaccinated according to the local EPI schedule (exclusive of oral polio vaccine birth dose).
  • A parent or guardian is willing to attend all planned study visits or allow home visits and mobile phone contacts, as required by the protocol.

Exclusion Criteria

  • Previous receipt any measles-containing vaccine.
  • Previous receipt of any yellow fever vaccine.
  • Previous receipt of any meningitis vaccine.
  • Receipt of rotavirus vaccine within the past 90 days.
  • Administration of any other vaccine within 8 weeks prior to administration of study vaccines or planned vaccination during the 4 weeks after study vaccination.
  • History of allergic disease or known hypersensitivity to any component of the study vaccines and/or following administration of vaccines included in the local program of immunization
  • Use of any investigational or non-registered drug within 90 days prior to the administration of study vaccines.
  • Administration of immunoglobulins and/or any blood products within 90 days prior to the administration of study vaccines or planned administration during the vaccine period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents since birth (including systemic corticosteroids, this means prednisone, or equivalent, ≥0.5 mg/kg/day; topical steroids including inhaled steroids are allowed).
  • A family history of congenital or hereditary immunodeficiency.
  • History of intussusception.
  • Uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception.
  • Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history or physical examination, which in the opinion of the investigator, might interfere with the study objectives.
  • Acute illness at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with fever [axillary temperature ≥38°C] or without fever [severity determined at the discretion of the investigator]. Acute illness is a temporary exclusion.
  • Any condition or criterion that in the opinion of the investigator might compromise the well-being of the subject or the compliance with study procedures or interfere with the outcome of the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02286895). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search